Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Autor:	Dumont, Clément, Baciarello, Giulia, Bosset, Pierre-Olivier, Lavaud, Pernelle, Colomba, Emeline, Massard, Christophe, Loriot, Yohann, Albiges, Laurence, Blanchard, Pierre, Bossi, Alberto, Nenan, Soazig, Fizazi, Karim
Zdroj:	Clinical Genitourinary Cancer; December 2020, Vol. 18 Issue: 6 p444-451, 8p
Abstrakt:	Neoadjuvant chemotherapy with docetaxel and estramustine (DE) significantly improved relapse-free survival in patients with high-risk localized prostate cancer treated with androgen deprivation therapy (ADT) for 3 years and a local treatment in the GETUG-12 phase III trial. We sought to explore whether the addition of DE impacts long-term treatment-related side effects.
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect